NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Sample comparison of BÜHLMANN fCAL Turbo and OC-FCa faecal calprotectin methods.

Author(s): O'Driscoll S, Piggott C, Benton SC

Publication: Ann Clin Biochem, 2025, Vol. 62, Page 67-70

PubMed ID: 39093620 PubMed Review Paper? No

Purpose of Paper

This paper compared the risk classification for calprotectin, a marker of gastrointestinal inflammation, of case-matched homogenized and non-homogenized fecal specimens using two different processing and analysis methods: OC Sensor fCAL and the BUHLMANN fCAL Turbo.

Conclusion of Paper

Among homogenized fecal specimens, there was a positive bias of 67.3% when the OC Sensor fCAL (OC-FCa method was compared with the BUHLMANN fCAL Turbo method (P < 0.00001).  Among homogenized specimens, the agreement between the two methods that were classified as having normal (<50 μg/g), borderline (50-150 μg/g), and elevated (>150 μg/g) calprotectin were k = 0.794, k = 0.52, and k = 0.788, respectively. Among non-homogenized specimens, there was a positive bias of 88.4% when the OC-FCa method was compared with the fCAL Turbo method (P <0.0001).  The agreement between the two methods for non-homogenized specimens that were classified as normal (<50 μg/g), borderline (50-150 μg/g) and elevated (>150 μg/g) calprotectin were k = 0.02, k = 002, and k = 0.596, respectively.  The authors conclude that the OC-FCa method results in a positive bias in calprotectin levels compared to the fCAL Turbo method and thus cut-off values need to be adjusted accordingly. 

Studies

  1. Study Purpose

    This study compared the calprotectin risk classification of case-matched homogenized and non-homogenized fecal specimens using two different specimen processing and analysis pathways: OC Sensor fCAL and the BUHLMANN fCAL Turbo. In total, 111 homogenized and 49 non-homogenized surplus, anonymized fecal specimens were obtained (details not provided). All specimens were thawed at room temperature for 1 h and loaded into both an OC-Auto Sampling Bottle 3 and a BUHLMANN CALEX Cap device. Non-homogenized specimens were analyzed the same day, while homogenized were stored overnight at 4°C, which fell within the manufacturer’s specifications. Calprotectin was quantified  in OC samples using an OC-Sensor Pledia analyser, in fCAL Turbo homogenized specimens  on a Roche Cobas 8000, and in fCAL Turbo non-homogenized specimens using an Abbott Alinity instrument. Specimens with <26 µg/g calprotectin were excluded from analysis. Calprotectin levels were classified as normal (<50 μg/g), borderline (50–150 μg/g), or elevated (>150 μg/g).

    Summary of Findings:

    Among homogenized fecal specimens, there was a positive bias of 67.3% when the OC Sensor fCAL (OC- Among homogenized fecal specimens, there was a positive bias of 67.3% when the OC Sensor fCAL (OC-FCa method was compared with the BUHLMANN fCAL Turbo method (P < 0.00001).  Among homogenized specimens, the agreement between the two methods that were classified as having normal (<50 μg/g), borderline (50-150 μg/g), and elevated (>150 μg/g) calprotectin were k = 0.794, k = 0.52, and k = 0.788, respectively. Among non-homogenized specimens, there was a positive bias of 88.4% when the OC-FCa method was compared with the fCAL Turbo method (P <0.0001).  The agreement between the two methods for non-homogenized specimens that were classified as normal (<50 μg/g), borderline (50-150 μg/g) and elevated (>150 μg/g) calprotectin were k = 0.02, k = 002, and k = 0.596, respectively.  The authors conclude that the OC-FCa method results in a positive bias in calprotectin levels compared to the fCAL Turbo method and thus cut-off values need to be adjusted accordingly. 

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Not specified
    • Irritable Bowel Syndrome
    Platform:
    AnalyteTechnology Platform
    Protein Clinical chemistry/auto analyzer
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Biospecimen Acquisition Method of fluid acquisition Different fecal collection procedures compared
    Clinical chemistry/auto analyzer Specific Technology platform OC-FCa method
    BUHLMANN fCAL Turbo method
    Biospecimen Aliquots and Components Biospecimen mixing Homogenized
    Not homogenized

You Recently Viewed  

News and Announcements

  • New Articles on the GTEx Project are Now FREELY Available!

  • Just Published!

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • More...